MX2019000251A - Composiciones y metodos que comprenden mejoras de los arn guias de crispr usando el promotor h1. - Google Patents
Composiciones y metodos que comprenden mejoras de los arn guias de crispr usando el promotor h1.Info
- Publication number
- MX2019000251A MX2019000251A MX2019000251A MX2019000251A MX2019000251A MX 2019000251 A MX2019000251 A MX 2019000251A MX 2019000251 A MX2019000251 A MX 2019000251A MX 2019000251 A MX2019000251 A MX 2019000251A MX 2019000251 A MX2019000251 A MX 2019000251A
- Authority
- MX
- Mexico
- Prior art keywords
- addition
- promoter
- crispr
- modifications
- sequences
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La materia aquí descrita proporciona composiciones y métodos que comprenden mejoras de un sistema CRISPR (por ejemplo, CRISPR-proteína asociada (cas) 9 (sistema CRISPR-cas9, sistemas CRISPR sin cas9). Tales composiciones pueden comprender modificaciones en la región promotora H1, además de modificaciones en UTR 5´, diferentes secuencias ortólogas del promotor H1, nuevas secuencias del promotor bidireccional compacto con actividad tanto Pol II como Pol III, adición de secuencias de consenso de Kozak, secuencias de terminación, adición de la expresión condicional del promotor bidireccional Pol Il/Pol III, adición de una secuencia molde donante para corregir mutaciones, o combinaciones de las mismas. Otros aspectos de la invención se relacionan con modificaciones de cas9 a través de fusiones de regulación postranscripcional del ciclo celular, sitios diana parciales diseñados por ingeniería genética de manera tal que la nucleasa puede unirse a ellos sin escindir el ADN, sitios de autorregulación, y modificaciones n-terminales para modular la semivida.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662358335P | 2016-07-05 | 2016-07-05 | |
PCT/US2017/040707 WO2018009534A1 (en) | 2016-07-05 | 2017-07-05 | Compositions and methods comprising improvements of crispr guide rnas using the h1 promoter |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019000251A true MX2019000251A (es) | 2019-10-09 |
Family
ID=60912275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019000251A MX2019000251A (es) | 2016-07-05 | 2017-07-05 | Composiciones y metodos que comprenden mejoras de los arn guias de crispr usando el promotor h1. |
Country Status (14)
Country | Link |
---|---|
US (1) | US11766488B2 (es) |
EP (1) | EP3481956A4 (es) |
JP (2) | JP2019520078A (es) |
KR (1) | KR20190039702A (es) |
CN (1) | CN109844116A (es) |
AU (2) | AU2017292667A1 (es) |
BR (1) | BR112019000055A2 (es) |
CA (1) | CA3029860A1 (es) |
CL (1) | CL2019000025A1 (es) |
EA (1) | EA201990213A1 (es) |
IL (1) | IL264020A (es) |
MX (1) | MX2019000251A (es) |
SG (1) | SG11201900038QA (es) |
WO (1) | WO2018009534A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3111479A1 (en) * | 2017-09-26 | 2019-04-04 | The Board Of Trustees Of The University Of Illinois | Crispr/cas system and method for genome editing and modulating transcription |
CA3082450A1 (en) | 2017-11-21 | 2019-05-31 | Crispr Therapeutics Ag | Materials and methods for treatment of autosomal dominant retinitis pigmentosa |
CN108728441B (zh) * | 2018-04-18 | 2022-07-22 | 深圳市第二人民医院 | 特异性识别p53突变的基因*** |
GB2589246A (en) | 2018-05-16 | 2021-05-26 | Synthego Corp | Methods and systems for guide RNA design and use |
JPWO2019225638A1 (ja) * | 2018-05-25 | 2021-07-29 | 国立大学法人 筑波大学 | 融合タンパク質、核酸、細胞及び動物の製造方法 |
JPWO2020059708A1 (ja) * | 2018-09-17 | 2021-09-02 | 国立大学法人 東京医科歯科大学 | Casタンパク質の活性調節法 |
CN113166754A (zh) | 2018-10-16 | 2021-07-23 | 蓝色等位基因有限责任公司 | 用于将dna靶向***基因中的方法 |
US20200140893A1 (en) * | 2018-11-01 | 2020-05-07 | Blueallele, Llc | Methods for altering gene expression for genetic disorders |
EP3878513A4 (en) * | 2018-11-08 | 2022-08-31 | National University Corporation Tokai National Higher Education and Research System | GENE THERAPY USING SINGLE AAV VECTOR GENOEDITTING |
EP3990636A1 (en) * | 2019-06-28 | 2022-05-04 | CRISPR Therapeutics AG | Materials and methods for controlling gene editing |
EP3997221A4 (en) * | 2019-07-08 | 2023-07-05 | Inscripta, Inc. | INCREASED NUCLEIC ACID-DRIVEN CELL EDIT VIA A LEXA-RAD51 FUSION PROTEIN |
CN110622921B (zh) * | 2019-09-29 | 2021-06-15 | 江苏大学 | 阿尔茨海默病病变区FoxG1过表达小鼠模型的构建方法及应用 |
CN110607302A (zh) * | 2019-10-09 | 2019-12-24 | 广州医科大学附属第二医院 | 检测花生四烯酸脂氧合酶aloxe3基因启动子突变的方法及其应用 |
CN111718933B (zh) * | 2020-06-28 | 2022-01-28 | 暨南大学 | 一种rrbp1基因敲除热带爪蛙模型的制备方法与应用 |
WO2022212768A2 (en) * | 2021-03-31 | 2022-10-06 | Hunterian Medicine Llc | Compact promoters for gene editing |
WO2023120536A1 (ja) * | 2021-12-21 | 2023-06-29 | 国立大学法人東海国立大学機構 | 単一のaavベクターによるゲノム編集を用いた遺伝子治療 |
WO2024050547A2 (en) * | 2022-09-02 | 2024-03-07 | Hunterian Medicine Llc | Compact bidirectional promoters for gene expression |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4198626A (en) | 1977-09-02 | 1980-04-15 | Rauscher Frank J | Intravenous alarm device |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US4931777A (en) | 1988-11-16 | 1990-06-05 | Chiang Cheng San | Low level alarm for drop-feed injection liquid |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5112319A (en) | 1991-05-14 | 1992-05-12 | Eric Lai | Infusion alarm system |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
US6121555A (en) | 1997-10-10 | 2000-09-19 | Northgate Technologies Incorporated | Fluid container sensor |
US7750817B2 (en) | 1999-12-10 | 2010-07-06 | Beverage Metrics Holding Ltd | System and method using a scale for monitoring the dispensing of a beverage |
JP2001343294A (ja) | 2000-05-31 | 2001-12-14 | Ishida Co Ltd | ロードセル及び秤 |
GB0130955D0 (en) | 2001-12-24 | 2002-02-13 | Cancer Res Ventures | Expression system |
US7180015B2 (en) | 2004-09-24 | 2007-02-20 | Hudson Douglas A | Scale with clampable protrusion for weighing bicycles and other sports-related items |
US10022457B2 (en) * | 2005-08-05 | 2018-07-17 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
US20070106177A1 (en) | 2005-10-11 | 2007-05-10 | Yoshito Hama | Apparatus for collecting and calculating quantity of patient fluid loss and method of using same |
US20080293142A1 (en) * | 2007-04-19 | 2008-11-27 | The Board Of Regents For Oklahoma State University | Multiple shRNA Expression Vectors and Methods of Construction |
KR101196701B1 (ko) | 2009-07-16 | 2012-11-07 | 주식회사 실티 | 가축용 자동 급수장치 |
US8889394B2 (en) | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
WO2012166662A1 (en) | 2011-05-27 | 2012-12-06 | Pet Wireless, Llc | Systems, methods and computer program products for monitoring the behavior, health, and/or characteristics of an animal |
JP7085716B2 (ja) * | 2013-06-05 | 2022-06-17 | デューク ユニバーシティ | Rnaガイド遺伝子編集及び遺伝子調節 |
US20150251894A1 (en) | 2014-03-06 | 2015-09-10 | Julie Barbara Lake | Transportable Device for Automatically Filling Water Buckets, Troughs and Containers |
DK3116997T3 (da) * | 2014-03-10 | 2019-08-19 | Editas Medicine Inc | Crispr/cas-relaterede fremgangsmåder og sammensætninger til behandling af lebers kongenitale amaurose 10 (lca10) |
CA2943622A1 (en) * | 2014-03-25 | 2015-10-01 | Editas Medicine Inc. | Crispr/cas-related methods and compositions for treating hiv infection and aids |
EA039693B1 (ru) * | 2014-06-16 | 2022-02-28 | Дзе Джонс Хопкинс Юниверсити | Композиции и способы для экспрессии рнк-проводников crispr с использованием промотора h1 |
EP2982758A1 (en) | 2014-08-04 | 2016-02-10 | Centre Hospitalier Universitaire Vaudois (CHUV) | Genome editing for the treatment of huntington's disease |
US20160090603A1 (en) | 2014-09-30 | 2016-03-31 | Sandia Corporation | Delivery platforms for the domestication of algae and plants |
EP3204496A1 (en) * | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
KR20230098910A (ko) * | 2014-10-31 | 2023-07-04 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도 |
CA2963820A1 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
CN104531632A (zh) * | 2014-11-18 | 2015-04-22 | 李云英 | 快速降解的Cas9-ODC422-461融合蛋白及其应用 |
CA2970370A1 (en) * | 2014-12-24 | 2016-06-30 | Massachusetts Institute Of Technology | Crispr having or associated with destabilization domains |
CN204440762U (zh) | 2015-02-09 | 2015-07-01 | 刘苹芳 | 阿基米德原理演示仪 |
EP3313445A1 (en) | 2015-06-24 | 2018-05-02 | Sigma Aldrich Co. LLC | Cell cycle dependent genome regulation and modification |
GB2541459B (en) | 2015-08-21 | 2021-01-13 | Carton Bernard | A method and system for monitoring pregnancy toxaemia |
-
2017
- 2017-07-05 WO PCT/US2017/040707 patent/WO2018009534A1/en unknown
- 2017-07-05 AU AU2017292667A patent/AU2017292667A1/en not_active Abandoned
- 2017-07-05 MX MX2019000251A patent/MX2019000251A/es unknown
- 2017-07-05 EP EP17824801.9A patent/EP3481956A4/en active Pending
- 2017-07-05 CN CN201780054074.5A patent/CN109844116A/zh active Pending
- 2017-07-05 BR BR112019000055-0A patent/BR112019000055A2/pt not_active Application Discontinuation
- 2017-07-05 JP JP2019500231A patent/JP2019520078A/ja not_active Withdrawn
- 2017-07-05 US US16/315,458 patent/US11766488B2/en active Active
- 2017-07-05 CA CA3029860A patent/CA3029860A1/en active Pending
- 2017-07-05 KR KR1020197003436A patent/KR20190039702A/ko not_active Application Discontinuation
- 2017-07-05 EA EA201990213A patent/EA201990213A1/ru unknown
- 2017-07-05 SG SG11201900038QA patent/SG11201900038QA/en unknown
-
2018
- 2018-12-30 IL IL264020A patent/IL264020A/en unknown
-
2019
- 2019-01-04 CL CL2019000025A patent/CL2019000025A1/es unknown
-
2022
- 2022-07-29 JP JP2022121572A patent/JP2022153576A/ja active Pending
-
2023
- 2023-11-14 AU AU2023266246A patent/AU2023266246A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EA201990213A1 (ru) | 2019-11-29 |
EP3481956A1 (en) | 2019-05-15 |
JP2022153576A (ja) | 2022-10-12 |
BR112019000055A2 (pt) | 2019-04-02 |
CL2019000025A1 (es) | 2019-06-21 |
SG11201900038QA (en) | 2019-02-27 |
EP3481956A4 (en) | 2020-07-08 |
US20190314521A1 (en) | 2019-10-17 |
IL264020A (en) | 2019-02-03 |
KR20190039702A (ko) | 2019-04-15 |
AU2023266246A1 (en) | 2023-12-07 |
US11766488B2 (en) | 2023-09-26 |
AU2017292667A1 (en) | 2019-02-21 |
WO2018009534A1 (en) | 2018-01-11 |
JP2019520078A (ja) | 2019-07-18 |
CA3029860A1 (en) | 2018-01-11 |
CN109844116A (zh) | 2019-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019000251A (es) | Composiciones y metodos que comprenden mejoras de los arn guias de crispr usando el promotor h1. | |
PH12021550843A1 (en) | Nucleic acid constructs and methods of use | |
WO2018209158A3 (en) | CRISPR / RNA GUIDED NUCLEASE SYSTEMS AND METHODS | |
WO2015191693A3 (en) | Method for gene editing | |
MX2019008401A (es) | Sistema de mango de rasurado para sostener un cartucho giratorio alrededor de dos ejes. | |
MX2020013124A (es) | Nucleasas guiadas por acido ribonucleico (arn) y fragmentos activos y variantes de los mismos y metodos de uso. | |
MX2022004786A (es) | Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular. | |
WO2016205688A3 (en) | Rna-guided transcriptional regulation and methods of using the same for the treatment of back pain | |
MX2018004160A (es) | Secuencias 3´ utr para estabilización de arn. | |
MX2019009361A (es) | Composiciones y metodos para el tratamiento de hemoglobinopatias. | |
MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
WO2019051122A3 (en) | CONDITIONAL ACTIVATED BOND FRACTIONS CONTAINING FC REGIONS | |
MX2020011939A (es) | Nuevas enzimas y sistemas crispr. | |
AU2016262093A8 (en) | Enhancing endonuclease based gene editing in primary cells | |
WO2018191502A3 (en) | Anti-cd137 antibodies and methods of use thereof | |
BR112016029178A2 (pt) | composições e métodos para a expressão de rnas guia de crispr usando o promotor h1 | |
MX2021004214A (es) | Composiciones y metodos de inmunoterapia. | |
MX2019006510A (es) | Sistema y metodos para el biocontrol de patogenos en plantas. | |
EP4249042A3 (en) | Modular implant delivery and positioning system | |
MX2017015511A (es) | Soporte de jeringa y autoinyector. | |
GB2552605A (en) | Enhancing functionalities of virtual assistants and dialog systems via plugin marketplace | |
WO2014144592A3 (en) | Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing | |
MX2019006475A (es) | Sistemas y métodos para dirección con arn guía puntual (arngp) de adn endógeno y fuente. | |
EP4053285A4 (en) | GUIDE RNA MODIFIED TO INCREASE THE EFFICIENCY OF CRISPR/CAS12F1 SYSTEM, AND ITS USE | |
WO2019094791A3 (en) | Targeted crispr delivery platforms |